Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study
This post hoc analysis suggests that with longer lorlatinib exposure, no new safety signals emerged, and treatment discontinuation due to AEs remained low after 5 years of follow-up. Most AEs were effectively managed with dose modifications, indicating that current management strategies can be effective to mitigate toxicity. ClinicalTrials.gov NCT03052608.
Authors
- Holger Thurm
- Takako Inoue (ORCID: https://orcid.org/0009-0002-8698-0590)
- Todd M. Bauer (ORCID: https://orcid.org/0000-0002-3078-5043)
- Benjamin Solomon (ORCID: https://orcid.org/0000-0003-3059-5730)
- Diego Cortinovis (ORCID: https://orcid.org/0000-0001-7611-7369)
- Julien Mazières (ORCID: https://orcid.org/0000-0002-5921-7613)
- Anna Polli
- Geoffrey Liu (ORCID: https://orcid.org/0000-0002-2603-7296)
- Dong‐Wan Kim
- Richu Sharma
Institutions
- Inserm (FR)
- Pfizer (United States) (US)
- Peter MacCallum Cancer Centre (AU)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- Centre de Recherches en Cancérologie de Toulouse (FR)
- Osaka International Cancer Institute (JP)
- Tennessee Oncology (US)
- Pfizer (Italy) (IT)
- Osaka International Cancer Institute (JP)
- Artemis Hospitals (IN)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf287
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer